Product Description
BB-1701 is being developed by Bliss Biopharmaceutical for the treatment of Locally Advanced/Metastatic HER2 Positive Solid Tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04257110?term=BB-1701&draw=2&rank=1)
Mechanisms of Action: HER2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eisai
Company Location:
Company Founding Year: 1941
Additional Commercial Interests: Bliss Biopharmaceutical (Hangzhou)
Clinical Description
Countries in Clinic: Canada, China, France, Germany, Japan, Spain, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Phase 1: Bladder Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04257110 |
BB-1701-101 | P1 |
Completed |
Colorectal Cancer|Bladder Cancer|Gastrointestinal Cancer|Breast Cancer|Esophageal Cancer |
2024-08-31 |
21% |
2025-07-25 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT06188559 |
BB-1701-G000-205 | P2 |
Completed |
Breast Cancer |
2026-03-18 |
12% |
2026-05-23 |
|
jRCT2031230750 |
jRCT2031230750 | P2 |
Recruiting |
Breast Cancer |
2027-09-30 |
|||
2023-506866-30-00 |
BB-1701-G000-205 | P2 |
Completed |
Breast Cancer |
2025-04-29 |
2025-05-02 |
Treatments |
|
CTR20243614 |
CTR20243614 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20231518 |
CTR20231518 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20241422 |
CTR20241422 | P2 |
Recruiting |
Breast Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/05/2024 |
News Article |
Eisai Accelerates Progress In Oncology Research With New Data At Esmo Congress 2024 |
|
05/23/2024 |
News Article |
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
|
05/23/2023 |
News Article |
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
|
05/07/2023 |
News Article |
BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701 |